CAMBRIDGE, Mass, Feb. 28, 2017 /CNW/ -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today announced that Ankit Mahadevia, President and CEO, will present a corporate overview at the following upcoming conferences.
- Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:30 a.m. ET in Boston, MA
- Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at 3:20 p.m. ET in New York, NY
Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections. Spero Therapeutics is advancing two lead programs in parallel, SPR741 and SPR994. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant gram negative infections, such as Enterobacteriaceae and Acinetobacter baumanii, including carbapenem resistant strains. SPR741 increases the spectrum and potency of more than two dozen classes of gram positive antibiotics to include activity against multidrug resistant gram negative infections when used in combination. SPR994 is a novel oral agent that has demonstrated potent in–vitro activity against a wide variety of gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and gram-positive bacteria. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections.
For more information, please visit www.sperotherapeutics.com
SOURCE Spero Therapeutics
For further information: Spectrum Science Communications: Maia Arnold, PhD, Senior Scientific Executive, 202-955-6222 x2506, [email protected]; INVESTOR CONTACT: Stern Investor Relations, Beth DelGiacco, Vice President, 212-362-1200, [email protected], http://www.sperotherapeutics.com